{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T11:20:55Z","timestamp":1721733655427},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of the Study:<\/jats:title>\n            <jats:p>In 2003, our institution adopted triweekly carboplatin (tCb) area under the curve (AUC) 5 as an alternative to high-dose cisplatin (100 mg\/m<jats:sup>2<\/jats:sup>) for select patients receiving definitive concurrent chemoradiation for locally advanced laryngeal carcinoma (LALC). Here, we present our experience and outcomes with this definitive concurrent chemoradiation regimen.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>From January 2003 through December 2013, 53 patients with stage III (60%) or IVA (40%) LALC were treated with tCb AUC 5 and concurrent radiotherapy to 70 Gy without neoadjuvant chemotherapy. Reasons for using carboplatin instead of cisplatin in these patients were: age 70 and older (21%), poor renal function (6%), presence of 1 or more major comorbid condition(s) (36%), and per discretion of the treating medical oncologist (38%). Primary disease site was glottis in 22 (42%) patients and supraglottis in 31 (58%) patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Median follow-up time was 63 months for surviving patients. Out of the 53 patients, 43 (81%) received all 3 cycles of carboplatin and all patients received their intended dose of radiotherapy. Although 17 (32%) patients required a feeding tube during treatment, only 2 (4%) required it long term. There were no acute treatment-related grade 4 or 5 hematologic toxicities. On last follow-up, 14 (26%) patients had died of intercurrent disease. For the subgroup of \u201cRTOG 9111 eligible\u201d patients in our cohort (n=46), 5-year estimates of overall survival, disease-free survival, laryngectomy-free survival, larynx preservation, and locoregional control were: 49%, 42%, 39%, 80%, and 63%, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>In patients with LALC who are suboptimal candidates for high-dose cisplatin, our experience suggests that tCb AUC 5 with concurrent radiotherapy provides acceptable outcomes with tolerable toxicity.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/coc.0000000000000330","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T08:50:11Z","timestamp":1474015811000},"page":"595-600","source":"Crossref","is-referenced-by-count":3,"title":["Concurrent Radiotherapy and Triweekly Carboplatin for the Definitive Treatment of Locally Advanced Laryngeal Carcinoma"],"prefix":"10.1097","volume":"41","author":[{"given":"Sharon M.","family":"Lu","sequence":"first","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shawn","family":"Iganej","sequence":"additional","affiliation":[{"name":"Radiation Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iman A.","family":"Abdalla","sequence":"additional","affiliation":[{"name":"Medical Oncology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary L.","family":"Buchschacher","sequence":"additional","affiliation":[{"name":"Medical Oncology, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230903","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJM199106133242402","article-title":"Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer","volume":"324","year":"1991","journal-title":"N Engl J Med"},{"issue":"no. 22","key":"R2-20230903","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa031317","article-title":"Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer","volume":"349","author":"Forastiere","year":"2003","journal-title":"N Engl J Med"},{"issue":"no. 4","key":"R3-20230903","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099","volume":"16","author":"Al-Sarraf","year":"1998","journal-title":"J Clin Oncol"},{"issue":"no. 1","key":"R4-20230903","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1200\/JCO.2003.01.008","article-title":"An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer","volume":"21","author":"Adelstein","year":"2003","journal-title":"J Clin Oncol"},{"issue":"no. 29","key":"R5-20230903","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J Clin Oncol"},{"key":"R6-20230903","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","article-title":"Carboplatin dosage: Prospective evaluation of a simple formula based on renal function","volume":"7","author":"Calvert","year":"1989","journal-title":"J Clin Oncol"},{"issue":"no. 4","key":"R7-20230903","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1200\/JCO.1992.10.4.520","article-title":"Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer","volume":"10","author":"Jodrell","year":"1992","journal-title":"J Clin Oncol"},{"issue":"no. 1","key":"R8-20230903","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.clon.2010.09.007","article-title":"Carboplatin chemotherapy in patients with recurrent high-grade glioma","volume":"23","author":"Murray","year":"2011","journal-title":"Clin Oncol"},{"issue":"no. 2","key":"R9-20230903","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1385\/MO:21:2:095","article-title":"Concomitant radiochemotherapy vs radiotherapy alone in patients with head and neck cancer","volume":"21","author":"Fountzilas","year":"2004","journal-title":"Med Oncol"},{"issue":"no. 9208","key":"R10-20230903","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(00)90011-4","article-title":"Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data","volume":"355","author":"Pignon","year":"2000","journal-title":"Lancet"},{"issue":"no. 1","key":"R11-20230903","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0167-8140(97)00048-0","article-title":"Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial","volume":"43","author":"Jeremic","year":"1997","journal-title":"Radiother Oncol"},{"issue":"no. 24","key":"R12-20230903","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1093\/jnci\/91.24.2081","article-title":"Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma","volume":"91","author":"Calais","year":"1999","journal-title":"J Natl Cancer Inst"},{"issue":"no. 7","key":"R13-20230903","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1200\/JCO.2012.43.6097","article-title":"Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer","volume":"31","author":"Forastiere","year":"2013","journal-title":"J Clin Oncol"},{"issue":"no. 1","key":"R14-20230903","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.clon.2005.08.014","article-title":"Carboplatin and hypofractionated accelerated radiotherapy: a dose escalation study of an outpatient chemoradiation schedule for squamous cell carcinoma of the head and neck","volume":"18","author":"Madhava","year":"2006","journal-title":"Clin Oncol"},{"issue":"no. 6","key":"R15-20230903","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1056\/NEJMoa053422","article-title":"Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck","volume":"354","author":"Bonner","year":"2006","journal-title":"N Engl J Med"},{"issue":"no. 4","key":"R16-20230903","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.ijrobp.2010.07.008","article-title":"Concurrent cisplatin and radiation versus cetuximab and radiation for locally advanced head-and-neck cancer","volume":"81","author":"Koutcher","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"no. 3","key":"R17-20230903","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/hed.23609","article-title":"Concurrent cetuximab versus platinum-based chemoradiation for the definitive treatment of locoregionally advanced head and neck cancer","volume":"37","author":"Tang","year":"2015","journal-title":"Head Neck"},{"issue":"no. 2","key":"R18-20230903","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/S1470-2045(14)71200-8","article-title":"Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial","volume":"16","author":"Giralt","year":"2015","journal-title":"Lancet Oncol"},{"key":"R19-20230903","article-title":"Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial","author":"Magrini","year":"2015","journal-title":"J Clin Oncol"},{"key":"R20-20230903","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.radonc.2009.04.014","article-title":"Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients","volume":"92","author":"Pignon","year":"2009","journal-title":"Radiother Oncol"},{"key":"R21-20230903","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.rpor.2012.07.014","article-title":"Squamous cell carcinoma of the head and neck in the elderly","volume":"18","author":"Gugi\u0107","year":"2013","journal-title":"Report Pract Oncol Radiother"},{"key":"R22-20230903","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jgo.2016.01.010","article-title":"Concurrent chemoradiotherapy in older adults with squamous cell head & neck cancer: evidence and management","volume":"7","author":"Verma","year":"2016","journal-title":"J Geriat Oncol"},{"key":"R23-20230903","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1002\/cncr.29956","article-title":"Survival outcomes with concurrent chemoradiation for elderly patients with locally advanced head and neck cancer according to the National Cancer Data Base","volume":"122","author":"Amini","year":"2016","journal-title":"Cancer"}],"container-title":["American Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00000421-201806000-00012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T03:01:43Z","timestamp":1693710103000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00000421-201806000-00012"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/coc.0000000000000330","relation":{},"ISSN":["0277-3732"],"issn-type":[{"value":"0277-3732","type":"print"}],"subject":[],"published":{"date-parts":[[2018,6]]}}}